Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Average Price Target from Analysts

Posted by George Bondi on May 21st, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) has been given an average rating of “Moderate Buy” by the nine research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $32.50.

A number of equities analysts have commented on the company. Guggenheim reduced their target price on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. JPMorgan Chase & Co. increased their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Wells Fargo & Company reduced their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th.

Check Out Our Latest Stock Analysis on GLUE

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, insider Edmund Dunn sold 25,164 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the completion of the transaction, the insider owned 22,693 shares of the company’s stock, valued at $410,743.30. This represents a 52.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total value of $97,950.72. Following the transaction, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at $10,993,400.32. The trade was a 0.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 37,150 shares of company stock valued at $668,694 over the last quarter. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Monte Rosa Therapeutics by 73.3% during the first quarter. Bank of America Corp DE now owns 387,542 shares of the company’s stock valued at $6,375,000 after acquiring an additional 163,971 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Monte Rosa Therapeutics in the first quarter valued at approximately $11,294,000. Empowered Funds LLC increased its holdings in shares of Monte Rosa Therapeutics by 9.8% in the first quarter. Empowered Funds LLC now owns 305,398 shares of the company’s stock valued at $5,024,000 after purchasing an additional 27,321 shares during the last quarter. Exome Asset Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the first quarter valued at approximately $2,953,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Monte Rosa Therapeutics by 55.8% in the first quarter. The Manufacturers Life Insurance Company now owns 209,801 shares of the company’s stock valued at $3,451,000 after purchasing an additional 75,127 shares during the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Trading Up 6.1%

Shares of GLUE stock opened at $18.65 on Friday. The company has a market capitalization of $1.58 billion, a P/E ratio of -12.60 and a beta of 1.62. The business’s 50 day moving average is $17.81 and its two-hundred day moving average is $17.88. Monte Rosa Therapeutics has a 12-month low of $3.84 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, research analysts predict that Monte Rosa Therapeutics will post -1.23 earnings per share for the current fiscal year.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.